Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986617 | 1.00 | NPC1 (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL2493301 | 1.00 | NPC1 (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL3390440 | 0.87 | ALDH1A1 (0.34) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL3497068 | 0.84 | CES2 (0.34) | NPC1RAB9AMGLLALDH1A1P2RX7 | |
| SCHEMBL6842407 | 0.79 | SLC6A2 (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL5707587 | 0.79 | SLC6A2 (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL2907033 | 0.79 | SLC6A2 (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL8960840 | 0.79 | SLC6A2 (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL5044476 | 0.77 | SLC6A2 (0.33) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3395341 | 0.77 | HTT (0.33) | NPC1RAB9AMGLLSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1639121-A4 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-04-16 | — | — | EP | claimed |
| EP-1639121-A2 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2006-03-29 | — | — | EP | claimed |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | claimed |
| WO-2005003374-A2 | SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2005-01-13 | — | — | WO | claimed |
| US-9029345-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-8981078-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130004945-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114847-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100111839-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J | 2010-05-06 | — | — | US | disclosed |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111839-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | RPA1, RPA3, PCNA | NPC1 1593/4885RAB9A 2705/4885MGLL 2554/4885 |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | REV1, PCNA, DNA2 | NPC1 2427/4885RAB9A 1981/4885MGLL 2507/4885 |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | DUT, DERA, RNASEL | NPC1 1401/4885RAB9A 2712/4885MGLL 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.